Analytic review of modeling studies of ARV based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Dimitrov, Dobromir ^a,c   Boily, Marie Claude ^b   Brown, Elizabeth R ^a,c   Hallett, Timothy B ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG USE; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MATHEMATICAL MODEL; PRE EXPOSURE PROPHYLAXIS; PREDICTION; PREVALENCE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL;

EID: 84896689388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080927     Document Type: Review

References (46)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine 363: 2587-2599
2. Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science 329(5996): 1168-1174
3. Centers of Disease Control and Prevention (2011) CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection among Heterosexuals, Press Release. Available: http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals. html. Accessed 04 January 2013.
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine 367: 399-410
5. FHI (2011) FHI Statement on the FEM-PrEP HIV Prevention Study, FHI360, Press Release. Available: http://www.fhi360.org/en/AboutFHI/Media/Releases/FEM- PrEPstatement041811.htm. Accessed 04 January 2013.
6. Jeanne Marrazzo GR, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. (2013) Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). Conference on Retroviruses and Opportunistic Infections. Atlanta, GA.
7. Food and Drug Administration (2012) FDA approves first drug for reducing the risk of sexually acquired HIV infection. Press Release. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 04 January 2013.
8. Centers of Disease Control and Prevention (2011) Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. Morbidity and Mortality Weekly Report 60(03): 65-68
9. Centers of Disease Control and Prevention (2012) CDC Issues Interim Guidance on Use of Medication to Prevent HIV Infection among Heterosexually Active Adults, Press Release. Available: http://www.cdc.gov/nchhstp/newsroom/ 2012/PrEP-HeterosexualGuidance-PressRelease.html. Accessed 04 January 2013.
10. The Consensus Committee, Southern African HIV Clinicians Society, chaired by Linda-Gail Bekker and Kevin Rebe (2012) Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection, Southern African Journal of HIV Medicine 13 (2): 40-55
11. Karmon E, Potts M, Getz WM (2003) Microbicides and HIV: Help or hindrance? JAIDS 34: 71-75. (Pubitemid 37100115)
12. Breban R, McGowan I, Topaz C, Schwartz EJ, Anton P, et al. (2006) Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. Mathematical Biosciences and Engineering 3: 459-466
13. Chen FH (2006) The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 20: 1551-1553
14. Vickerman P, Watts C, Delany S, Alary M, Rees H, et al. (2006) The importance of context: Model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sexually Transmitted Diseases 33: 397-405 (Pubitemid 43833029)
15. Abbas UL, Anderson RM, Mellors JW (2007) Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings. PLoS ONE 2: e875
16. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839
17. Vissers DCJ, Voeten HACM, Nagelkerke NJD, Habbema JDF, de Vlas SJ (2008) The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A simulation Study. PLoS ONE 3: e2077
18. Vickerman PD, Foss AP, Watts CP (2008) Using Modeling to Explore the Degree to Which a Microbicide's Sexually Transmitted Infection Efficacy May Contribute to the HIV Effectiveness Measured in Phase 3 Microbicide Trials. JAIDS 48(4): 460-467
19. Wilson DP, Coplan PM, Wainberg MA, Blower SM (2008) The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics, Proceedings of The National Academy of Sciences of The United States of America 105: 9835-984
20. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. Clinical Infectious Diseases 48: 806-815
21. Supervie V, Garcia-Lerma JG, Heneine W, Blower S (2010) HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proceedings of The National Academy of Sciences of The United States of America 107: 12381-12386
22. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B (2010) Evaluating the Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) and Its Impact on HIV-1 Transmission in South Africa. PLoS ONE 5: e13646
23. Dimitrov DT, Masse B, Boily MC (2010) Who Will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries? Statistical Communications in Infectious Diseases 2(1): Article 4.
24. Abbas UL, Hood G, Wetzel AW, Mellors JW (2011) Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP). PloS ONE 6:e18165
25. Dimitrov DT, Boily MC, Baggaley R, Mâsse B (2011) Modeling the Gender-Specific Impact of Vaginal Microbicides on HIV Transmission. Journal of Theoretical Biology 288: 9-20
26. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, et al. (2011) Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci. Rep., 1: 185
27. Boily MC, Dimitrov D, Karim Salim SA, Masse B (2011) The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. SEXUALLY TRANSMITTED INFECTIONS 87(7): 646-653
28. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. Plos Medicine 8: e1001123
29. Williams BG, Karim SSA, Karim QA, Gouws E (2011) Epidemiological Impact of Tenofovir Gel on the HIV Epidemic in South Africa, Jaids-Journal of Acquired Immune Deficiency Syndromes, 58, 207-210.
30. Cox AP, Foss AM, Shafer LA, Nsubuga RN, Vickerman P, et al. (2011) Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda. Sexually Transmitted Infections, 87, 629-634.
31. Baggaley R, Powers K, Boily M (2011) What do mathematical models tell us about the emergence and spread of drug-resistant HIV? Current Opinion in HIV and AIDS 6: 131-140
32. The HIV Modelling Consortium (2011) The Potential for the Spread of Drug Resistance Due to PrEP. Meeting Report. Available: http://sites.google.com/site/ hivmodelling/work-packages/drug-resistance-caused-by-prep. Accessed 04 January 2013.
33. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, et al. (2001) Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy 45: 2733-2739 (Pubitemid 32906664)
34. Louie M, Hogan C, Hurley A, Simon V, Chung C, et al. (2003) Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 17: 1151-1156 (Pubitemid 36667757)
35. Prada N, Davis B, Jean-Pierre P, La Roche M, Duh FM, et al. (2008) Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. Jaids 49: 117-122
36. Statistics South Africa (2010) Mid-year population estimates. Available: http://www.statssa.gov.za/publications/P0302/P03022010.pdf. Accessed 04 Jan 2013.
37. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, et al. (2010) A Decline in New HIV Infections in South Africa: Estimating HIV Incidence from Three National HIV Surveys in 2002, 2005 and 2008. Plos One 5: e11094
38. Boily MC, Baggaley RF, Wang L, Masse B, White RG, et al. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infectious Diseases 9: 118-129.
39. UNAIDS/WHO (2009) AIDS epidemic update: November 2009 UNAIDS/World Health Organization, Geneva. Available: http://www.unaids.org/en/media/unaids/ contentassets/dataimport/pub/report/2009/jc1700-epi-update-2009-en.pdf. Accessed 13 Sept 2013.
40. Ferry B, Carael M, Buve A, Auvert B, Laourou M, et al. (2001) Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. AIDS 15: S41-S50. (Pubitemid 32913003)
41. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, et al. (2002) HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 16: 597-603. (Pubitemid 34218855)
42. Porter K, Zaba B (2004) The empirical evidence for the impact of HIV on adult mortality in the developing world: data from serological studies. AIDS 18: S9-S17. (Pubitemid 39037465)
43. Johnson L, Dorrington R, Bradshaw D, Pillay-Van Wyk V, Rehle T (2009) Sexual behaviour patterns in South Africa and their association with the spread of HIV: insights from a mathematical model. Demographic Research 21: 289-340.
44. Kalichman SC, Simbayi LC, Cain D, Jooste S (2009) Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sexually Transmitted Infections 85: 411-415.
45. Todd J, Cremin I, McGrath N, Bwanika J-B, Wringe A, et al. (2009) Reported number of sexual partners: comparison of data from four African longitudinal studies Sexually Transmitted Infections, 85, i72-i80
46. Foss AM, Hossain M, Vickerman PT, Watts CH (2007) A systematic review of published evidence on intervention impact on condom use in sub-Saharan Africa and Asia. Sexually Transmitted Infections 83: 510-516. (Pubitemid 350290969)